(Q40964738)

reason for preferred rank

25 September 2017

title

Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial (English)

1 reference

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

8 April 2023

Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363253

8 April 2023

1 reference

1 reference

1 reference

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

8 April 2023

1

Muss HB

1 reference

25 September 2017

Richards F 2nd

3

1 reference

25 September 2017

D. R. White

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363253

8 April 2023

F. Richards

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363253

8 April 2023

M. R. Cooper

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363253

8 April 2023

J. J. Stuart

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363253

8 April 2023

D. V. Jackson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363253

8 April 2023

L. Rhyne

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363253

8 April 2023

C. L. Spurr

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363253

8 April 2023

language of work or name

English

0 references

publication date

1 November 1978

1 reference

full work available at URL

25 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

1 reference

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

8 April 2023

1 reference

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

8 April 2023

1 reference

25 September 2017

volume

42

1 reference

25 September 2017

issue

5

1 reference

25 September 2017

page(s)

2141-2148

1 reference

Combination Chemotherapy for Advanced Breast Cancer: Response and Effect on Survival

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197811%2942%3A5%3C2141%3A%3AAID-CNCR2820420509%3E3.0.CO%3B2-3

A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy

21 January 2018

4

1 reference

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard

8 April 2023

7

1 reference

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

Chemotherapy of disseminated breast cancer:Current status and prospects

8 April 2023

8

1 reference

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer

8 April 2023

13

1 reference

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study

8 April 2023

16

1 reference

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer

8 April 2023

17

1 reference

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project

8 April 2023

19

1 reference

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity

8 April 2023

21

1 reference

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2141::AID-CNCR2820420509%3E3.0.CO;2-3

8 April 2023

Identifiers

10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3

1 reference

25 September 2017

1 reference